schering-plough

CEOs who cut the most jobs during the recession earned an average of 42% more than their S&P 500 peers, according to a study by the Institute for Policy Studies. Top execs at the 50 firms that laid off the most workers since the economic crisis began averaged nearly $12 million in 2009.

Two federal agencies are investigating whether drugmaker Merck & Co. violated the Foreign Corrupt Practices Act, which bars U.S. companies from bribing foreign officials.

Pharmaceutical giant Merck & Co. reported Friday its second-quarter net income fell 51% on higher restructuring and merger costs. But adjusted earnings beat analysts' estimates.

Now that they are nearly done squeezing Swiss bank UBS for information about its wealthy tax-dodging clients, the IRS and the Justice Department are moving on to new tax fraud targets: Clients of London-based bank HSBC Holdings, mostly those with ties to India and Singapore.

News that Amylin Pharmaceuticals (AMLN) inked a billion-dollar development deal with Takeda Pharmaceutical for new obesity therapies was among the favorable developments in the sector on Monday that pushed several key stocks higher. Amylin shares were up nearly 10 percent in late trading after...

Merck & Co., Inc. (MRK) announced today that its shareholders voted by an overwhelming 99 percent to approve a proposed $41 billion merger with Schering-Plough Corp. (SGP). Schering-Plough's shareholders, whose meeting started much later, were also quick to approve the deal with the same...

Sanofi-Aventis (SNY) -- which only yesterday reported that its second-quarter profit surged 29.4 percent as net sales increased by 11.2 percent, beat estimates and raised 2009 guidance -- today announced it would purchase Merck & Co.'s (MRK) 50 percent stake in their Merial animal-health...

Major drug companies are declining more than the general market today, but none like Merck & Co. (MRK). Merck's shares dropped 2.5 percent on news it won't seek approval this year for its heart-failure drug rolofylline after preliminary results of a Phase III study failed to meet...

Merck & Co. (MRK) reported first-quarter earnings Tuesday morning. The drugmaker posted a 57 percent drop in first-quarter income to $1.43 billion, or 67 cents per share. Excluding items, earnings were 74 cents a share, below consensus estimates of 77 cents a share. Similarly, revenue declined...

Despite taking a nosedive around noon, stocks managed to extend the week's rally and the Dow Jones Industrial Average closed up about 54 points, or 0.75 percent, at 7,224. Some of the Dow's most battered members posted the biggest gains: General Motors (GM) and Citigroup (C) both rose, capping...